Ocuphire Pharma Investor Day Presentation Deck
RM
46
Nyxol Product Candidate Profile
Novel, Differentiated Alpha 1/2 Blocker Eye Drop for Refractive Indications
Effective
Nyxol: 0.75% Phentolamine Ophthalmic Solution
Preservative Free, EDTA Free, and Stable
Favorable Safety Profile
Nyxol Improves Vision by
Decreasing Pupil Size (1 to
1.5mm)
Nyxol Clinical Trials
↑ Near & Distance Visual
Acuity
↑ Contrast Sensitivity (night)
No Systemic Effects
No Changes in Blood Pressure
No Changes in Heart Rate
Well-Tolerated Topical Effects
Mild, Transient, Reversible Eye
Redness
IOP Unchanged or Decreased
No Headaches
Favorable safety profile vs
competitors
Durable
Effects Last ≥ 24 Hours
Chronic daily dosing of Nyxol
at bedtime reduced pupil size
for up to 24 - 36 hours
With nighttime use, patients
wake up without eye redness
Ocuphire
PHARMAView entire presentation